Mantle cell lymphoma (MCL) is an aggressive lymphoid malignancy for which better treatment strategies are needed. To identify potential diagnostic and therapeutic targets, a signature consisting of MCL-associated genes was selected based on a comprehensive gene expression analysis of malignant and normal B cells. The corresponding protein epitope signature tags were identified and used to raise monospecific, polyclonal antibodies, which were subsequently analyzed on paraffin-embedded sections of malignant and normal tissue. In this study, we demonstrate that the initial selection strategy of MCLassociated genes successfully allows identification of protein antigens either uniquely expressed or overexpressed in MCL compared with normal lymphoid tissues.
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Mantle cell lymphoma (MCL)
1 is an aggressive and in many cases an incurable malignancy with a median survival time of 3 years (1, 2), and improved diagnostic tools as well as new therapeutic strategies are needed. In the quest for identifying prognostic, diagnostic, and therapeutic targets, gene expression profiling has during the last 5-6 years proven to be a useful tool in cancer research in general and in B cell lymphoma research in particular (3, 4) . Most studies have focused on prognostic (5) (6) (7) (8) and diagnostic factors (6, 9 -11) , whereas fewer have focused on identification (12) or evaluation (13) of new therapeutic targets. In studies of MCL, transcriptional profiling has revealed genes involved in altered apoptotic pathways, increased proliferation, and aggressive behavior (5, 12, 14 -21) . Although numerous deregulated genes have been identified, little information regarding the potential use of the corresponding gene products for predictive diagnosis or therapy is available. Thus, MCL-associated proteins and their role in pathogenesis and potential use in disease prediction and/or therapy need to be evaluated.
To allow analysis of the numerous deregulated gene products identified by gene expression profiling, a parallel approach is also necessary for downstream investigations. To study individual tumor-associated proteins and their expression pattern, highly specific affinity probes are required. We addressed the challenge of generating such antibodies in a high throughput manner using an approach recently described by Agaton et al. (22) who showed that protein epitope signature tags (PrESTs), having 100% homology with the target, can be used to raise monospecific antibodies.
Analysis of the MCL-derived proteome has been performed previously using commercially available antibody microarrays containing 512 different antibodies, and deregulated proteins were found as compared with normal CD19 ϩ B cells (23) .
Similarly whole-proteome analysis, based on 2D gels and MALDI-TOF MS, was used to analyze biopsies from two MCL tumors, and nine proteins were found to be up-regulated in MCL compared with reactive lymph nodes (24) . These approaches to the analysis of differences in protein content in malignant and non-malignant samples are based on a low number of analytes in comparison with gene expression profiling where Ͼ45,000 transcripts can be screened using e.g. an Affymetrix U133 Plus 2.0 array. Tissue microarrays or staining of full tissue sections is commonly used to confirm the expression of proteins or gene products shown to be deregulated in different types of malignancies. However, due to limited availability of antibodies targeting many of the poorly characterized gene products that can be identified using whole genome analysis, new strategies to confirm expression of the corresponding gene products need to be established. Consequently in a rational genomic and proteomic approach we narrowed down the number of potential targets in MCL by confirming gene ex-pression data in a high throughput manner on the protein level using novel PrEST-specific antibodies against MCL-associated antigens. This enabled us to analyze the expression and localization of both known and unknown gene products in different tissues and cells, independently of the availability of commercially available antibodies, and to initiate the direct process to identify potential diagnostic and therapeutic lymphoma targets.
EXPERIMENTAL PROCEDURES
Selection of Candidate Genes-The MCL-associated genes were derived using gene expression profiling (U95v2, Affymetrix, Santa Clara, CA) of tumor samples from 19 patients diagnosed with MCL. As reference, 11 samples from five different B cell populations, derived from normal pediatric tonsils (Malmoe University Hospital), were used as described previously (9, 12) . The different B cell populations used were: naïve B cells (CD19
, and memory B cells (CD19 ϩ , CD38
Ϫ , IgD Ϫ ). When filtering the data for differentially regulated genes, all samples were scaled to a fixed median value as recommended by Affymetrix. When represented in the heat map ( Fig. 1) , all samples were normalized to the naïve B cell population (two replicates) using "Normalize to specific samples" in Gene Spring 7.0 (Agilent Technologies Inc., Palo Alto, CA).
After filtering of the data, three main categories of genes were selected.
1. Genes that were quantitatively overexpressed (Ͼ2-fold) in the majority (Ͼ80%) of MCL patient samples compared with normal B cell populations. 2. Genes that were qualitatively (i.e. present versus absent) overexpressed in the majority (Ͼ80%) of MCL patient samples compared with normal B cell populations. These genes were not expressed in any of the normal B cell populations analyzed. 3. Genes that were qualitatively overexpressed in a subgroup (Ͼ30%) of MCL patients compared with normal B cell populations. These genes were not expressed in any of the normal B cell populations analyzed.
Generation and Analysis of the Affinity Reagents-Suitable PrESTs, representing unique regions for each target protein were designed using bioinformatic tools (25) and with the human genome sequence as template (26) . In the design of the PrESTs, transmembrane regions and signal peptides were avoided, and an amino acid sequence, with a size between 100 and 150 amino acids, with low homology to other human proteins was selected to decrease the risk of cross-reactivity of antibodies to other human proteins. The cloning and protein expression were performed as described previously (22) .
The monospecific antibodies were subsequently obtained by affinity purification of rabbit polyclonal antisera (27) . The antibodies were quality-controlled using a protein array and Western blots procedure as described by Uhlen et al. (28) .
Case Selection-A total of 25 cases of non-Hodgkin lymphoma were collected from the files of the Department of Pathology, The University of Schleswig-Holstein, Campus Lü beck, between 2004 and 2005. All cases were diagnosed and classified using morphologic and immunophenotypic criteria specified in the World Health Organization classification of lymphoid neoplasms (29) . The group of B cell non-Hodgkin lymphoma cases assessed included the following: eight mantle cell lymphoma (six small cell or classical and two blastoid), four follicular lymphoma (all grade 1 or 2), one nodal marginal zone B cell lymphoma, two lymphoplasmacytic lymphoma, and three small lymphocytic lymphoma/chronic lymphocytic leukemia. Non-neoplastic lymphoid tissues were included, represented by tonsils with follicular hyperplasia and tonsils with Epstein-Barr virus infection. All cases were analyzed using either tissue microarrays (n ϭ 25) or full tissue sections (n ϭ 2). The tissue microarrays included duplicate cores from all cases and were constructed using a manual tissue arrayer (AlphaMetrix Biotech GmbH, Rö dermark, Germany). All neoplasms assessed were fixed in 10% buffered formalin, routinely processed, and embedded in paraffin.
Immunohistochemical Methods-The immunohistochemical methods used in this study have been described previously (30) . Briefly heat-induced antigen retrieval was performed prior to immunohistochemical staining. Sections were incubated with a polyclonal antibody (0.1-1 g/slide) at room temperature for 30 min. Detection of signal was achieved using the ChemMate TM EnVision TM detection kit peroxidase/DAB (3,3Ј-diaminobenzidine), rabbit/mouse LSABϩ kit (DAKO, Hamburg, Germany) that contains secondary biotinylated goat anti-rabbit/mouse antibody and streptavidin/horseradish peroxidase complex according to the manufacturer's recommendations. 3,3Ј-Diaminobenzidine/H 2 O 2 (DAKO) was used as chromogen, and slides were counterstained with hematoxylin.
Scoring of Positive Cells in IHC-Defined staining patterns were noticed for the various antibodies, and a cutoff of 2% of stained cells was used to categorize an antibody as positive. Cytoplasmic or nuclear staining was also considered, and expression was graded visually as negative, weak, or moderate/strong. A lymphoma case was considered weakly positive if cytoplasmic staining was similar to or less than that of normal cells and moderate to strongly positive if cytoplasmic staining was similar to or greater than that of normal cells. 
TABLE I 96 selected MCL-associated genes
The genes were selected as described under "Experimental Procedures" and are ordered according to Fig. 1 . Antibodies against the same antigen separated by "/" are raised against different PrEST sequences (i.e. different epitopes), whereas antibodies separated by "-" are raised against the same PrEST sequence (i.e. the same epitopes). TM, transmembrane; ITIM, immunoreceptor tyrosine based inhibitory motif; NMB, neuromedin B; AE, adipocyte enhancer; FERM, 4.1 ezrin radixin moesin; GEF, guanine nucleotide exchange factor; LIM, Lin-11, Isl-1, Mec-3; SATB, special AT-rich binding protein; BTB, BR-C, ttk, and bab; KH, K homology; TEL, translocation-ets-leukemia. 
Filtering for MCL-associated Genes and Subsequent
PrEST Selection-After comprehensive analysis of differentially expressed genes in which 19 MCL samples and five normal tonsil-derived B cell populations were compared we chose 96 genes (see "Experimental Procedures") for subsequent PrEST identification. Because the most important aim of the study was to identify gene products potentially useful for prognosis and therapy, all the selected genes were quantitatively or qualitatively overexpressed in MCL as compared with normal B cell populations ( Fig. 1 and Table I ). Furthermore the selection of genes was focused mainly on poorly or presently non-characterized gene products.
Generation of PrEST-specific Antibodies-One or two unique PrESTs were identified for each of the 96 genes using the designed algorithm. From these 96 PrESTs we managed to generate 83 specific antibodies, whereas the remaining PrESTs did not produce well or did not generate a successful immune response. The 83 monospecific, polyclonal rabbit antibodies targeted in total 57 different antigens represented by one or two PrESTs, demonstrating an overall efficiency of the process of ϳ60%. After purification by affinity chromatography all antibodies had concentrations in the range of 0.02-0.4 mg/ml and passed the different quality controls, including PrEST microarray analysis (28) . The antibodies were subsequently analyzed by IHC on several different lymphomas.
Immunohistochemistry Analysis-The quality-controlled, monospecific antibodies were then evaluated using IHC on paraffin-embedded tissue sections from MCL, follicular lymphoma (FL), chronic lymphocytic lymphoma (CLL), marginal zone (MGZ) lymphoma, and tonsils. A 2% cutoff of positive cells was set to determine the antibody reactivity, although in most positive cases the percentage of positive cells was over 50% of tumor cells or defined cell populations, respectively. Most of the tested antibodies (84%, 70 of 83) showed reactivity to one or more of the tissues as shown in Fig. 2 . In accordance with the preselection strategy of gene products, the majority (80%, 56 of 70) of the reactive antibodies showed staining of MCL tumor cells (Fig. 2) . Among these 56 MCLreactive antibodies, 45% (25 of 56) showed a tumor specificity and did not react with either normal B cell-containing regions, such as the mantle zone cells and the germinal center (GC), or with plasma cells (Fig. 3a) . Staining of non-malignant cells was mostly seen in professional antigen-presenting cells, such as follicular dendritic cells (FDCs) and macrophages, whereas T cells were negative. Furthermore of the 25 MCL-, non-B cell-reacting antibodies, 14 (HPRK250003, -6, -7, -26, -27, -33, -34, -35, -51, -53, -54, -57, -60, and -78) strictly recognized lymphoma tissues and none of the tested normal tissue(s). Four antibodies (HPRK250033, -34, -53, and -60) showed an even further tumor selectivity in that they only recognized MCL and no other tested tissue. The reactivity pattern of these antibodies are of interest and are specifically marked (*) in Fig. 3a . One example of immunohistochemical staining of an MCL-reactive, non-B cell-reactive antibody (HPRK250026) on MCL and tonsil tissue sections is shown in Fig. 3b ; it also illustrates the distinct reactivity pattern often seen with the polyclonal, anti-PrEST antibodies. Furthermore when we analyzed the reactivity pattern of the MCL-associated antibodies we found that nine antibodies (HPRK250015, -33, -34, -36, -38, -41, -53, -60, and -93) were able to separate MCL from the other lymphoma types that were tested, such as FL and CLL. One example of such an antibody (HPRK250027) is shown in Fig. 4 where it is shown to be able to discriminate between a mantle cell and a follicular lymphoma.
The antibodies were further filtered in silico to find a general lymphoma-associated staining pattern. Twenty-six of the antibodies (n ϭ 26 of 83) passed the arbitrary criteria that at least three of four tested lymphoma tissues (MCL, CLL, FL, and MGZ lymphoma) should be positive (Fig. 5a ). Furthermore six of these generally lymphoma-reactive antibodies did not react with any of the normal B cell subtypes and are marked (**) in Fig.   5a . Immunohistochemistry stainings using one of the lymphoma-reactive antibodies (HPRK250057) are shown in Fig. 5b . In summary, the overall staining reactivities derived using all 83 PrEST antibodies on a variety of normal and tumor tissue are schematically shown in Fig. 6 . Among others, different antibodies specific for MCL in particular or lymphomas in general (MCL, CCL, FL, and MGZ) are presented.
DISCUSSION
The increasing use of highly parallel gene expression analysis has generated a tremendous amount of information on the usage of specific genes in various malignancies (32, 33) . On the other hand, efficient methods to translate these data into the protein expression level need to be further developed to improve the knowledge of the role of the corresponding proteins in disease onset and progression. Attempts to develop antibody microarrays for proteomic analysis have showed significant progress over the last few years (34, 35) , although the capacity is presently not proteome-wide. Furthermore analysis of the human proteome is done using 2D gels and MS-MS but is biased toward high abundance proteins (36) and can presently not be considered truly high throughput. Thus, gene expression analyses are still an attractive starting point to efficiently focus interest on a limited number of genes in the human genome, and by combining such gene signatures with affinity proteomics, a rational and efficient approach can be taken toward identification of proteins of diagnostic and therapeutic potential. One of the advantages of using antibody-based analysis of deregulated proteins in malignant versus normal tissues is that protein expression in individual cells and cell types can be assessed. This is in contrast to methods where whole tissue proteomes are analyzed using 2D gel in combination with MALDI-TOF analysis for protein identification. Thus, in some studies, like for many gene expression analyses, it is the composition of different cell types and their protein expression that is analyzed rather than differences between individual malignant and non-malignant cells (24, 37) .
In this study we have designed a rational approach based on PrESTs (22) to produce 83 antibodies specific for 57 gene products associated with MCL as deciphered by gene expression profiling. The affinity-purified antibodies were then used to analyze the corresponding protein expression in both malignant and normal tissues to validate our process. The MCL-associated genes were initially selected using extensive gene expression analysis of normal and malignant B cells (see "Experimental Procedures"). Genes coding for uncharacterized or poorly characterized gene products were considered particular interesting for this type of analysis. Consequently the aim of the study was to (i) demonstrate a rational process, based on genomic information, for the generation of antibodies against differentially expressed proteins; (ii) investigate the protein expression patterns and localization in different normal and malignant tissues; and (iii) identify lead protein targets potentially useful in diagnostic and/or therapeutic applications.
To validate the differences seen in gene expression at the protein level, patient tissue material needs to be evaluated. Most tissue banks that are available consist of paraffin-embedded material as it takes less time to prepare, stores well, and retains cellular details better than frozen material (39) . Because routine, diagnostic immunohistochemical analyses are performed using this material, it is of importance that the generated antibodies are not only able to recognize native but also fixed antigen. Analysis of the different antibodies using IHC (Figs. 2-5) showed that 84% of the tested antibodies reacted toward one or more paraffin-treated and formalinfixed tissue. Even if there are no, to our knowledge, previous report regarding the success rate of generating antibodies reactive toward paraffin-treated antigens, the achieved success rate was considered very satisfactory. The high success rate seems to be a positive feature of the PrEST-derived antibodies because reactivity against paraffin-treated and fixed tissue often is poor for most monoclonal antibodies (40, 41) . The ability of the different antibodies to recognize native antigens expressed by different lymphoma cell lines was also successfully assessed using flow cytometry, although this needs to be confirmed on primary tumor cells (data not shown).
When analyzing the IHC data, several interesting subgroups of antibody specificity were identified as summarized in Fig. 6 . The gene selection strategy was clearly reflected in the reactivity pattern of the antibodies as the majority of functional antibodies (80%) reacted with MCL tissue (Fig. 2) . It was not surprising to find that not all of the functional antibodies reacted with MCL tissue as it is generally known that the correlation between mRNA and protein level is not absolute. Recently a 40% correlation between transcript and protein level was reported (42) that emphasizes the importance of integrated genomic and proteomic studies. Among the MCLreactive antibodies, 45% showed no reactivity to B cells or cells found in either the mantle zone or the germinal center (Fig. 3) . These antibodies are of interest as diagnostic and/or therapeutic candidates, and they are presently being further validated. Staining of normal cells was mostly seen in antigenpresenting cells, such as FDCs and tissue macrophages, whereas T cells showed no staining at all. One explanation for this observation might be the fact that antigen-presenting cells take up, process, and display tumor-associated antigens on their surface as part of their normal immune surveillance. Thus, the majority of the antibodies in Fig. 3a may potentially be specific for malignant compared with normal B cells. We also identified a number of antibodies that specifically recognize MCL as compared with the other lymphomas and that may represent antibodies of a diagnostic value. One example of such an antibody (HPRK250027) is shown in Fig. 4 where a very distinct staining pattern is displayed.
Interestingly a number of antibodies (n ϭ 25) not only recognized MCL but also other lymphomas, such as FL, CLL, 
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and MGZ lymphomas (Fig. 5) . Six of these antibodies with lymphoma-associated reactivity did not recognize any of the tested normal B cells but seemed to identify tumor-associated antigens.
In therapeutic settings, antibodies targeting pan-B cell antigens have shown a clinical effect in the treatment of B cell lymphomas and are surprisingly well tolerated by the patients with no or only mild side effects (43) . This demonstrates that antibodies recognizing both MCL and normal B cells have a therapeutic value, although our focus has been to identify MCL-associated antigens not found in normal B cells. The reason for this is that these antigens might have an even greater clinical benefit to the patient as therapeutic targets. In contrast, depletion of the T cell compartment is a potential life-threatening condition (44) that must be prevented, and it is therefore of interest to note that only seven of 83 antibodies analyzed seemed to recognize cells in the T cell zone (Fig. 2) . Detailed analysis of clinically well documented patient material is presently being performed before selecting antigens for further clinical studies and for generation of human recombinant antibodies, which are more suitable for clinical development and therapy (31) .
In summary, we have used gene expression analysis as a preselection tool to identify genes that are overexpressed in MCL, identifying potentially interesting targets for diagnosis and/or therapy. These genes formed the basis for a successful strategy using the PrEST concept to derive specific, polyclonal antibodies to identify lymphoma-associated protein signatures. Furthermore the derived antibodies displayed an ability to discriminate between tumor and normal tissue as well as to specifically recognize either mantle cell lymphomas alone or a group of several different lymphomas, which served as a validation of the strategy.
